검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | MMC (Mitomycin C, Mitomycin C (MMC)) Medical Enterprises Europe B.V.·Urinary Bladder Neoplasms 68 trials |
|---|---|
Overview Program | Mitomycin C (MMC) |
Overview Company | Medical Enterprises Europe B.V. |
Overview Modality | ANTIBODY |
Overview Target | Urinary Bladder Neoplasms |
Overview Indication | Non-Muscle-Invasive Bladder Cancer (NMIBC) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | inhibits jejunal MMC activity via OTR-dependent mechanisms with partial involvement of GLP-1R signaling but not NO pathway |
MoA Biomarker | biomarkers |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial.. Data are sparse on the value of perioperative systemic therapy in patients with resectable colorectal peritoneal-only metastases. This trial aimed to compare the efficacy of perioperative systemic therapy versus surgery alone in this populatio… |
Toxicology CRS | 36% |
Clinical Data Tier / Score | A · 34 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | MMC (Mitomycin C, Mitomycin C (MMC)) Medical Enterprises Europe B.V.·Urinary Bladder Neoplasms 68 trials |
|---|---|
Overview Program | Mitomycin C (MMC) |
Overview Company | Medical Enterprises Europe B.V. |
Overview Modality | ANTIBODY |
Overview Target | Urinary Bladder Neoplasms |
Overview Indication | Non-Muscle-Invasive Bladder Cancer (NMIBC) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | inhibits jejunal MMC activity via OTR-dependent mechanisms with partial involvement of GLP-1R signaling but not NO pathway |
MoA Biomarker | biomarkers |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial.. Data are sparse on the value of perioperative systemic therapy in patients with resectable colorectal peritoneal-only metastases. This trial aimed to compare the efficacy of perioperative systemic therapy versus surgery alone in this populatio… |
Toxicology CRS | 36% |
Clinical Data Tier / Score | A · 34 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교